JKJan Pieter R. Koopman

Jan Pieter R. Koopman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan Pieter R. Koopman has a total of 203 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Experimental human colonisation with non-toxigenic Clostridioides difficile: a placebo-controlled randomised clinical trial

    by A. D. O. Hensen, C. Harmanus, P. H. Verbeek-Menken, J. P. R. Koopman, O. A. C. Lamers, G. V. T. Roozen, J. J. Janse, M. Balke-Buijs, M. Y. E. C. van der Stoep, P. Meij, et al.

    Clostridioides difficile infections remain a major global healthcare burden, underscoring the need for novel therapies. Human colonisation models provide mechanistic insight into C. difficile colonisation and facilitate identification of novel intervention targets. We conducted a placebo-controlled, randomised clinical trial (NCT05693077) administering non-toxigenic C. difficile (NTCD) capsules to healthy participants to assess safety and colonisation as primary endpoints, and microbiota susceptibility as a secondary endpoint. A total of 69 healthy participants (18-45 years), not previously colonised with C. difficile and without recent antibiotic use, were enrolled following a health assessment. NTCD capsules administered for five consecutive days at low or high dose, was safe with no dose-response relationship in colonisation outcomes. Vancomycin pretreatment induced colonisation success: with 5% colonisation without, 32% after one day, and 84% after five days vancomycin pretreatment. Some participants that cleared vancomycin rapidly acquired non-challenge C. difficile strains prior to NTCD challenge. Microbiota profiling (using shotgun metagenomics) revealed reduced α-diversity and pronounced community restructuring. These findings highlight the impact of antibiotic-mediated microbiota disruption, the widespread environmental presence of C. difficile, and the feasibility of meaningful microbiota assessment in small-scale intervention trials, thereby providing a robust tool to investigate this globally impactful infection.


  • Open Access

    T cell responses in repeated controlled human schistosome infection compared to natural exposure

    by Emmanuella Driciru, Jan Pieter R. Koopman, Sanne Steenbergen, Friederike Sonnet, Koen A. Stam, Laura de Bes-Roeleveld, Eva Iliopoulou, Jacqueline J. Janse, Jeroen Sijtsma, Irene Nambuya, et al.

    In Schistosoma-endemic regions a lack of natural sterilizing immunity means individuals are repeatedly infected, treated and reinfected. Due to difficulties in tracking natural infection, kinetics of host immune response during these reinfections have not been elucidated. Here, we use repeated (3x) controlled-human-Schistosoma mansoni infection (CHI) to study how antigen-specific T cells develop during reinfection (NCT05085470 study). We compared these responses to naturally infected endemic Ugandan individuals (HALLMARK study). A mixed Th1/Th2/regulatory CD4+ T cell response develops in repeated CHI. Adult-worm-specific responses after repeated CHI were similar to endemic-natural infection. However, endemic participants showed differential responses to egg- and cercariae-antigens. Repeated CHI with sequential exposure to cercariae of different sexes (male-female-male) revealed an elevated CD4+ T cell cytokine response to adult-worm and egg-antigens. Our findings demonstrate that single-sex schistosome infection elicits adult-worm-specific T cell cytokine responses that reflect endemic-natural infection. This study advances our understanding of the immunology of schistosome (re)infection in the human host.


  • Open Access

    T cell responses in repeated controlled human schistosome infection compared to natural exposure

    by Emmanuella Driciru, Jan Pieter R. Koopman, Sanne Steenbergen, Friederike Sonnet, Koen A. Stam, Helena de Bes-Roeleveld, Eva Iliopoulou, Jacqueline J. Janse, Jeroen Sijtsma, Irene Nambuya, et al.

    Schistosomiasis affects over 250 million people, predominantly in Sub-Saharan Africa. In Schistosoma -endemic regions a lack of natural sterilizing immunity means individuals are repeatedly infected, treated and reinfected. Due to difficulties in tracking infection in endemic areas, the kinetics of the host immune response during these reinfections have not been elucidated. Here, we use repeated (3x) controlled human Schistosoma mansoni ( Sm ) infection (repeated CHI) to directly study how antigen-specific T cells develop during reinfection. We compared these responses to natural Sm -infected endemic Ugandan individuals. We report that a mixed Th1/Th2/regulatory CD4 + T cell response develops in repeated CHI, primarily against adult worm antigens. Adult worm-specific responses after repeated CHI were similar to those observed in naturally infected endemic participants. However, endemic participants showed differential responses to antigens from the egg and cercariae life-cycle stages. Repeated CHI (3x) with sequential exposure to Sm cercariae of different sexes (male-female-male) revealed an elevated CD4 + T cell cytokine response to adult worm and egg antigens. Our findings demonstrate that reinfection with single-sex schistosomes elicits adult worm-specific T cell cytokine responses that reflect endemic-natural infection, highlighting the translatability of the CHI model to natural infection in endemic settings. Overall, this study advances our understanding of how schistosome immune responses develop over reinfection cycles in the human host, thereby increasing our understanding of the immunology of natural schistosome (re)infection.

  • Top Cited Papers
    Open Access

    Single immunization with genetically attenuated Pf∆mei2 (GA2) parasites by mosquito bite in controlled human malaria infection: a placebo-controlled randomized trial

    by Geert V. T. Roozen, Roos van Schuijlenburg, Annefleur D. O. Hensen, Jan Pieter R. Koopman, Olivia A. C. Lamers, Fiona J. A. Geurten, Jeroen C. Sijtsma, Els Baalbergen, Jacqueline J. Janse, Séverine Chevalley-Maurel, et al.

    Malaria vaccines consisting of metabolically active Plasmodium falciparum (Pf) sporozoites can offer improved protection compared with currently deployed subunit vaccines. In a previous study, we demonstrated the superior protective efficacy of a three-dose regimen of late-arresting genetically attenuated parasites administered by mosquito bite (GA2-MB) compared with early-arresting counterparts (GA1-MB) against a homologous controlled human malaria infection. Encouraged by these results, we explored the potency of a single GA2-MB immunization in a placebo-controlled randomized trial. Primary outcomes were safety and tolerability, time-to-parasitemia and protective efficacy. Humoral and cellular immunological results were considered secondary outcomes. Here we report the safe administration of GA2-MB with no breakthrough malaria and sterile protection in nine of ten participants at 6 weeks after a single immunization with 50 GA2-infected mosquitoes, compared with none of five mock-immunized participants, against a homologous controlled human malaria infection. Immunization increased circulating Pf-specific polyfunctional effector memory CD4+ T cells coexpressing tumor necrosis factor and interleukin-2. This unprecedented 90% protective efficacy after a single low-dose immunization holds great promise for the potency of GA2 immunization. Future studies should demonstrate whether GA2 is similarly efficacious in pre-exposed populations and whether the favorable safety profile reported here holds up in larger groups. ClinicalTrials.gov registration: NCT05468606.


  • Open Access

    Clinical tolerance but no protective efficacy in a placebo-controlled trial of repeated controlled schistosome infection

    by Jan Pieter R. Koopman, Emma L. Houlder, Jacqueline J. Janse, Olivia. A.C. Lamers, Geert V.T. Roozen, Jeroen C. Sijtsma, Miriam Casacuberta-Partal, Stan T. Hilt, M.Y. Eileen C. van der Stoep, Inge M. van Amerongen-Westra, et al.

    BACKGROUND: Partial protective immunity to schistosomiasis develops over time, following repeated praziquantel (PZQ) treatment. Moreover, animals develop protective immunity after repeated immunization with irradiated cercariae. Here, we evaluated the development of natural immunity through consecutive exposure-treatment cycles with Schistosoma mansoni in healthy, Schistosoma -naive participants using single-sex, controlled human S. mansoni infection. METHODS: Twenty-four participants were randomized in a double-blinded (1:1) manner to either the reinfection group, which received 3 exposures (weeks 0, 9, and 18) to 20 male cercariae, or to the infection control group, which received 2 mock exposures with water (weeks 0 and 9) prior to cercariae exposure (week 18). Participants were treated with PZQ (or placebo) at weeks 8, 17, and 30. Attack rates (ARs) after the final exposure (weeks 19–30) using serum circulating anodic antigen (CAA) positivity were compared between groups. Adverse events (AEs) were collected for safety. RESULTS: Twenty-three participants completed the follow-up. No protective efficacy was observed, given an 82% (9 of 11) AR after the final exposure in the reinfection group and 92% (11 of 12) in the infection control group (protective efficacy 11%; 95% CI –24% to 35%; P = 0.5). Related AEs were higher after the first infection (45%) compared with the second (27%) and third (28%) infections. Severe acute schistosomiasis was observed after the first infections only (2 of 12 in the reinfection group and 2 of 12 in the infection control group). CONCLUSION: Repeated Schistosoma exposure and treatment cycles resulted in apparent clinical tolerance, with fewer symptoms reported following subsequent infections, but did not result in protection against reinfection. TRIAL REGISTRATION: ClinicalTrials.gov NCT05085470. FUNDING: European Research Council (ERC) Starting Grant (no. 101075876).


  • Top Cited Papers

    Early symptom-associated inflammatory responses shift to type 2 responses in controlled human schistosome infection

    by Emma L. Houlder, Koen A. Stam, Jan Pieter R. Koopman, Marion H. König, Marijke C. C. Langenberg, Marie-Astrid Hoogerwerf, Paula Niewold, Friederike Sonnet, Jacqueline J. Janse, Miriam Casacuberta Partal, et al.

    Schistosomiasis is an infection caused by contact with Schistosoma -contaminated water and affects more than 230 million people worldwide with varying morbidity. The roles of T helper 2 (T H 2) cells and regulatory immune responses in chronic infection are well documented, but less is known about human immune responses during acute infection. Here, we comprehensively map immune responses during controlled human Schistosoma mansoni infection using male or female cercariae. Immune responses to male or female parasite single-sex infection were comparable. An early T H 1-biased inflammatory response was observed at week 4 after infection, which was particularly apparent in individuals experiencing symptoms of acute schistosomiasis. By week 8 after infection, inflammatory responses were followed by an expansion of T H 2 and regulatory cell subsets. This study demonstrates the shift from T H 1 to both T H 2 and regulatory responses, typical of chronic schistosomiasis, in the absence of egg production and provides immunological insight into the clinical manifestations of acute schistosomiasis.


  • Open Access

    Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial

    by Manon L. M. Prins, Geert V. T. Roozen, Cilia. R. Pothast, Wesley Huisman, Rob van Binnendijk, Gerco Den Hartog, Vincent P. Kuiper, Corine Prins, Jacqueline J. Janse, Olivia. A. C. Lamers, et al.

    Fractional dosing can be a cost-effective vaccination strategy to accelerate individual and herd immunity in a pandemic. We assessed the immunogenicity and safety of primary intradermal (ID) vaccination, with a 1/5th dose compared with the standard intramuscular (IM) dose of mRNA-1273 in SARS-CoV-2 naïve persons. We conducted an open-label, non-inferiority, randomized controlled trial in the Netherlands between June and December 2021. One hundred and fifty healthy and SARS-CoV-2 naïve participants, aged 18–30 years, were randomized (1:1:1) to receive either two doses of 20 µg mRNA-1273 ID with a standard needle (SN) or the Bella-mu® needle (BM), or two doses of 100 µg IM, 28 days apart. The primary outcome was non-inferiority in seroconversion rates at day 43 (D43), defined as a neutralizing antibody concentration threshold of 465 IU/mL, the lowest response in the IM group. The non-inferiority margin was set at −15%. Neutralizing antibody concentrations at D43 were 1789 (95% CI: 1488–2150) in the IM and 1263 (951–1676) and 1295 (1020–1645) in the ID-SN and ID-BM groups, respectively. The absolute difference in seroconversion proportion between fractional and standard-dose groups was −13.95% (−24.31 to −3.60) for the ID-SN and −13.04% (−22.78 to −3.31) for the ID-BM group and exceeded the predefined non-inferiority margin. Although ID vaccination with 1/5th dose of mRNA-1273 did not meet the predefined non-inferior criteria, the neutralizing antibody concentrations in these groups are far above the proposed proxy for protection against severe disease (100 IU/mL), justifying this strategy in times of vaccine scarcity to accelerate mass protection against severe disease.


  • Top Cited Papers
    Open Access

    Safety and infectivity of female cercariae in Schistosoma-naïve, healthy participants: a controlled human Schistosoma mansoni infection study

    by Jan Pieter R. Koopman, Emma L. Houlder, Jacqueline J. Janse, Miriam Casacuberta-Partal, Olivia A.C. Lamers, Jeroen C. Sijtsma, Claudia de Dood, Stan T. Hilt, Arifa Ozir-Fazalalikhan, Vincent P. Kuiper, et al.


  • Open Access

    Changes in pro inflammatory and regulatory immune responses during controlled human schistosome infection and the development of clinical symptoms

    by Emma L. Houlder, Koen A. Stam, Jan Pieter R. Koopman, Marion H. König, Marijke C.C. Langenberg, Marie-Astrid Hoogerwerf, Paula Niewold, Friederike Sonnet, Jacqueline J. Janse, Miriam Casacuberta Partal, et al.

    Schistosomiasis is a prevalent helminthiasis, affecting over 230 million people worldwide, with varied, stage specific morbidity. Whilst the Th2 and regulatory immune responses in chronic infection have been relatively well studied, we have little understanding of human immune responses during acute infection. This is despite the initial infective stages being proposed as crucial targets for much-needed vaccine development. Here, we comprehensively map immune responses in male and female single-sex controlled human Schistosoma mansoni infection. Using unbiased, high dimensional techniques we show that human immune responses to male and female single-sex infection are comparable. An early Th1-biased inflammatory response was observed at week 4 post infection, which was particularly apparent in individuals experiencing symptoms of acute schistosomiasis. This included expansion of HLA-DR + effector memory T cells, CD38 + monocytes and an increase in serum IFNγ. By week 8 post infection these inflammatory responses were followed by an expansion of Th2 and of regulatory cell subsets, including IL-10 producing CD4 - CD8 - T cells, CD11c + atypical memory B cells and serum IL-10. This study provides immunological insight into the clinical manifestations of acute schistosomiasis, as well as critical context through which to understand the development of immune responses observed in natural infection. One sentence summary: Controlled human schistosome infection reveals cellular and cytokine responses to schistosome infection, with early inflammatory responses in symptomatic individuals at week 4 and a balanced Th1, Th2 and regulatory response in all participants by week 8.

  • Open Access

    Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis

    by E. L. Houlder, A. H. Costain, I. Nambuya, S. L. Brown, J. P. R. Koopman, M. C. C. Langenberg, J. J. Janse, M. A. Hoogerwerf, A. J. L. Ridley, J. E. Forde-Thomas, et al.

    Schistosomiasis is a parasitic disease affecting over 200 million people in multiple organs, including the lungs. Despite this, there is little understanding of pulmonary immune responses during schistosomiasis. Here, we show type-2 dominated lung immune responses in both patent (egg producing) and pre-patent (larval lung migration) murine Schistosoma mansoni (S. mansoni) infection. Human pre-patent S. mansoni infection pulmonary (sputum) samples revealed a mixed type-1/type-2 inflammatory cytokine profile, whilst a case-control study showed no significant pulmonary cytokine changes in endemic patent infection. However, schistosomiasis induced expansion of pulmonary type-2 conventional dendritic cells (cDC2s) in human and murine hosts, at both infection stages. Further, cDC2s were required for type-2 pulmonary inflammation in murine pre-patent or patent infection. These data elevate our fundamental understanding of pulmonary immune responses during schistosomiasis, which may be important for future vaccine design, as well as for understanding links between schistosomiasis and other lung diseases.